Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

News Daily News

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Michael O'Riordan

January 09, 2024

News Opinion CV Team Dispatch

May 2023 News Roundup

L.A. McKeown

May 01, 2023

News Conference News CRT 2023

‘Beeting’ In-stent Restenosis? Dietary Nitrate May Improve Outcomes

Yael L. Maxwell

February 27, 2023

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

L.A. McKeown

May 19, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2020

Shelley Wood

October 30, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Daily News

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

Michael O'Riordan

December 10, 2019

News Features

Subtherapeutic Heparin: As Stories Multiply, Concerns Mount

Yael L. Maxwell

November 27, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Conference News EuroPCR 2018

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Shelley Wood

May 24, 2018

News Daily News

Plaque Dislodgement Less Frequent With Transradial vs Transfemoral PCI

Michael O'Riordan

May 07, 2018

News Daily News

PCI Comparable to CABG in Left Main Coronary Disease: Meta-analysis

Michael O'Riordan

December 14, 2017

News Industry News

Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System

November 30, 2017

News Daily News

Despite the Strengths of Next-Gen DES, BMS Deserve a Place at the Cath Table, Review Asserts

Caitlin E. Cox

July 28, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

Presentation CHIP Florida 2017

Evolution of Left Main Percutaneous Revascularization Advancement to a Standard of Care

Presenter: David E. Kandzari

January 20, 2017

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Shelley Wood

April 13, 2016

Advertisement

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

May 2023 News Roundup

‘Beeting’ In-stent Restenosis? Dietary Nitrate May Improve Outcomes

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

TCTMD’s Top 10 Most Popular Stories for October 2020

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

Subtherapeutic Heparin: As Stories Multiply, Concerns Mount

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Plaque Dislodgement Less Frequent With Transradial vs Transfemoral PCI

PCI Comparable to CABG in Left Main Coronary Disease: Meta-analysis

Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System

Despite the Strengths of Next-Gen DES, BMS Deserve a Place at the Cath Table, Review Asserts

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Evolution of Left Main Percutaneous Revascularization Advancement to a Standard of Care

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content